CRSP CRISPR Therapeutics AG

Price (delayed)

$57.9

Market cap

$4.92B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.69

Enterprise value

$4.43B

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that ...

Highlights
CRSP's quick ratio is up by 38% YoY
The equity has increased by 12% YoY and by 11% QoQ
The company's gross profit has surged by 171% YoY but it fell by 27% QoQ
The revenue has surged by 171% year-on-year but it has declined by 27% since the previous quarter

Key stats

What are the main financial stats of CRSP
Market
Shares outstanding
84.92M
Market cap
$4.92B
Enterprise value
$4.43B
Valuations
Price to book (P/B)
2.23
Price to sales (P/S)
17.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.31
Earnings
Revenue
$271.71M
EBIT
-$214.84M
EBITDA
-$195.23M
Free cash flow
-$166.55M
Per share
EPS
-$2.69
Free cash flow per share
-$2.04
Book value per share
$25.96
Revenue per share
$3.32
TBVPS
$29.82
Balance sheet
Total assets
$2.44B
Total liabilities
$355.08M
Debt
$234.93M
Equity
$2.08B
Working capital
$2B
Liquidity
Debt to equity
0.11
Current ratio
17.81
Quick ratio
17.81
Net debt/EBITDA
2.48
Margins
EBITDA margin
-71.9%
Gross margin
100%
Net margin
-79.9%
Operating margin
-109.9%
Efficiency
Return on assets
-9.7%
Return on equity
-11.6%
Return on invested capital
-11.7%
Return on capital employed
-9.3%
Return on sales
-79.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
1.92%
1 week
9.04%
1 month
-10.69%
1 year
0.73%
YTD
-7.51%
QTD
7.2%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$271.71M
Gross profit
$271.71M
Operating income
-$298.64M
Net income
-$217.14M
Gross margin
100%
Net margin
-79.9%
The company's gross profit has surged by 171% YoY but it fell by 27% QoQ
The revenue has surged by 171% year-on-year but it has declined by 27% since the previous quarter
The net margin has dropped by 93% since the previous quarter but it has surged by 85% year-on-year
The operating margin has dropped by 83% since the previous quarter but it has surged by 80% year-on-year

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
2.23
P/S
17.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.31
The EPS has surged by 60% year-on-year but it has declined by 39% since the previous quarter
The price to book (P/B) is 32% lower than the 5-year quarterly average of 3.3 and 11% lower than the last 4 quarters average of 2.5
The equity has increased by 12% YoY and by 11% QoQ
The revenue has surged by 171% year-on-year but it has declined by 27% since the previous quarter
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 1365.1 and 14% lower than the last 4 quarters average of 20.3

Efficiency

How efficient is CRISPR Therapeutics AG business performance
The return on sales has dropped by 95% since the previous quarter but it has surged by 85% year-on-year
The ROE has soared by 57% YoY but it has contracted by 38% from the previous quarter
The company's return on assets has surged by 57% YoY but it fell by 39% QoQ
The ROIC has soared by 55% YoY but it fell by 44% QoQ

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio is up by 38% YoY
CRISPR Therapeutics AG's current ratio has increased by 37% YoY
The debt is 89% smaller than the equity
CRSP's debt to equity is down by 15% QoQ and by 15% YoY
The equity has increased by 12% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.